Lilly to sell legacy antibiotics, Ceclor and Vancocin, to China-based partner in $375M deal

More than two years after Lilly partnered with specialty drugmaker Eddingpharm to exclusively distribute its decades-old antibiotics — Ceclor and Vancocin — in mainland China, the US drugmaker is offloading the legacy products to the China-based company in a $375 million deal.